TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23228922
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy (BB) in lower risk patients
Study: 16416305
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (GFJ) with 0.25 mg triazolam
Study: 16416305
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (GFJ) with 15 mg quazepam
Study: 16416305
Drug: Control (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.25 mg triazolam without GFJ)
Study: 16416305
Drug: Control (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (15 mg quazepam without GFJ)
Study: 11188859
Drug: Older sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older sequential pattern (OS)
Study: 11007407
Drug: no preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: no preparation
Study: 19345072
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mirtazapine and paroxetine
Study: 19345072
Drug: Non-responders on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-responders on monotherapy
Study: 15722985
Drug: Oral polybacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral polybacterial lysate suspension
Study: 15722985
Drug: No-treatment clinical
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment clinical follow-up (control group)
Study: 12069142
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol 400 micrograms (two tablets of 200 micrograms each)
Study: 12069142
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets of vaginal placebo)
Study: 27672029
Drug: Pentolinium (nicotinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentolinium (nicotinic ganglion blocker)
Study: 22337287
Drug: PEG‐IFN2a (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN2a (90 mcg escalating to 180 mcg weekly for 48 weeks)
Study: 22337287
Drug: Standard clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard clinical care (no further antiviral therapy)
Study: 11896977
Drug: Topical repifermin
Normalized name: NEPIDERMIN
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical repifermin (recombinant human keratinocyte growth factor-2) applied for 12 weeks
Study: 2851877
Drug: 5 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg/day ganciclovir
Study: 2851877
Drug: 10 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg/day ganciclovir
Study: 31630398
Drug: Inhaled nitrous
Normalized name: nitrous oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitrous oxide (50:50 mix with oxygen)
Study: 31630398
Drug: Inhaled nitrous
Normalized name: nitrous oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitrous oxide (50:50 mix with oxygen) among parous women
Study: 24532260
Drug: Pomegranate extract
Normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate extract (PE) consumers (900 mg/day for 15 days)
Study: 9815866
Drug: Aspirin 250
Normalized name: aspirin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 250 mg and Ticlopidine 500 mg/d (A+T group)
Study: 9815866
Drug: Aspirin 250
Normalized name: aspirin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 250 mg/d and oral anticoagulation (A+OAC group)
Study: 2698587
Drug: Hemodilution with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodilution with repeated venesections (total 250-1000 ml) and concomitant dextran 40 administration
Study: 1124532
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral delta‐1‐(trans)‐tetrahydrocannabinol
Study: 1124532
Drug: oral delta‐1‐(trans)‐tetrahydrocannabinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral delta‐1‐(trans)‐tetrahydrocannabinol
Study: 31658381
Drug: AJM300 960
Approvals — FDA: no, EMA: no, PMDA: no
Description: AJM300 960 mg
Study: 31658381
Drug: AJM300 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: AJM300 240 mg
Study: 31658381
Drug: AJM300 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: AJM300 480 mg
Study: 30691468
Drug: Umeclidinium bromide/vilanterol
Normalized name: Umeclidinium Bromide/Vilanterol Trifenatate 62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium bromide/vilanterol 62.5/25 mcg
Study: 30691468
Drug: Tiotropium/olodaterol 5/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium/olodaterol 5/5 mcg
Study: 29544572
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus Simvastatin
Study: 26388147
Drug: Ketamine (acute,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (acute, subanaesthetic doses)
Study: 24320560
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 μg/kg
Study: 18166179
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg/d for 5 days starting on day 3 of menses; 115 patients, 243 cycles)
Study: 18166179
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC; 100 mg/d; 101 patients, 226 cycles)
Study: 14981835
Drug: Low-dose helical
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose helical CT with 10 mm collimation
Study: 14981835
Drug: Low-dose helical
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose helical CT with 8 mm collimation
Study: 14981835
Drug: Low-dose helical
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose helical CT with 5 mm collimation
Study: 14981835
Drug: Sequential subsection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential subsection scan of chest with 50 mA and 8 mm collimation
Study: 10099946
Drug: Detraining group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detraining group (stop normal training but continue activities of daily living)
Study: 30927159
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg PEA
Study: 30927159
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg PEA
Study: 26354213
Drug: Stem Cell
Normalized name: Stem cells, apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stem Cell Therapy (SCT) - infusion of 5-10 × 10^8 autologous mononuclear cells (MNC) by intra-coronary route
Study: 26354213
Drug: Standard Medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Medical Therapy (non SCT group)
Study: 26354213
Drug: Stem Cell
Normalized name: Stem cells, apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stem Cell Therapy (SCT) with cell dose ≥ 5 × 10^8 (n=71)
Study: 19731228
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose (600 mg intravenously in two divided doses, at least 24 hours apart, 14 days before surgery)
Study: 19731228
Drug: Placebo (given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (given intravenously in two divided doses, at least 24 hours apart, 14 days before surgery)
Study: 11312473
Drug: Etomidate 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.2 to 0.3 mg/kg (n = 10)
Study: 9726264
Drug: Intense outpatient
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense outpatient treatment
Study: 1599887
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 20 ml 0.375% bupivacaine with 1:200,000 epinephrine at a rate of 6 ml/hour during the first 24 hours postoperatively
Study: 1599887
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of 20 ml 0.375% bupivacaine with 1:200,000 epinephrine at four-hour intervals
Study: 31666259
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tryptophan and phenylalanine
Study: 31666259
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AAs
Study: 28002201
Drug: TX-004HR 10
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TX-004HR 10 μg
Study: 28002201
Drug: TX-004HR 25
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TX-004HR 25 μg
Study: 28002201
Drug: TX-004HR 4
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TX-004HR 4 μg
Study: 9139377
Drug: Nakayama strain
Normalized name: Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated Prefilled Syringe [Ixiaro]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nakayama strain JE vaccine
Study: 9139377
Drug: Beijing strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beijing strain JE vaccine
Study: 23183639
Drug: (S)-ketamine (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)-ketamine (serum target 50 ng/ml)
Study: 23183639
Drug: (S)-ketamine (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)-ketamine (serum target 10 ng/ml)
Study: 23183639
Drug: (S)-ketamine (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)-ketamine (serum target 30 ng/ml)
Study: 20077901
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education programme and fluoride toothpaste use under parental supervision
Study: 20077901
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education programme
Study: 12536735
Drug: Phosphocreatine (neoton)
Normalized name: phosphocysteamine
DrugBank: Phosphocreatine (DB13191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphocreatine (neoton) group (group CP) - 4.0 g neoton intravenously 2 days before operation
Study: 12536735
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group C) - 5% G. S instead of neoton
Study: 9434695
Drug: Cold blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold blood cardioplegia (4:1 dilution, blood/Plegisol, potassium chloride 15 mEq/L; n = 62)
Study: 2455425
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 25 mg methotrexate
Study: 2455425
Drug: Single intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intramuscular injection of 25 mg methotrexate
Study: 2455425
Drug: Long-term maintenance
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term maintenance methotrexate therapy
Study: 19465233
Drug: Fenofibrate 200
Normalized name: fenofibrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 200 mg per day
Study: 29096777
Drug: PedPRM (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PedPRM (2 mg escalated to 5 mg)
Study: 26296794
Drug: 250 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 μg roflumilast
Study: 26296794
Drug: 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg roflumilast
Study: 26296794
Drug: 1000 μg
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 μg roflumilast
Study: 19563187
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical acupoint stimulation and oral administration of placebo
Study: 19563187
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Mosapride citrate dispersible tablets, Domperidone, and Omeprazole with placebo treatment of transcutaneous electrical acupoint stimulation
Study: 11240871
Drug: Atropine 0.01
Normalized name: atropine 0.0194 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.01 mg.kg‐1
Study: 10193218
Drug: Metoclopramide 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.2 mg.kg‐1
Study: 11240871
Drug: Atropine 0.01
Normalized name: atropine 0.0194 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.01 mg.kg‐1 plus Metoclopramide 0.2 mg.kg‐1
Study: 3797469
Drug: Lithium levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium levels 0.46‐0.60 mEq/l (group B)
Study: 3797469
Drug: Lithium levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium levels 0.61‐0.75 mEq/l (group C)
Study: 3797469
Drug: Lithium levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium levels 0.76‐0.90 mEq/l (group D)
Study: 3797469
Drug: Lithium levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium levels 0.30‐0.45 mEq/l (group A)
Study: 31751547
Drug: Current epilepsy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current epilepsy treatments
Study: 31751547
Drug: Precision medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precision medicine for improved seizure control and reduced toxicity
Study: 29681046
Drug: Colchicine 1
Normalized name: colchicine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 1 g/day orally for two months
Study: 22050795
Drug: Follicular phase
Normalized name: Follicular hormone
DrugBank: Estrone (DB00655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Follicular phase (propofol anesthesia at 1.5-2.0 μg/mL)
Study: 22050795
Drug: Mid-late luteal
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-late luteal phase (propofol anesthesia at 1.5-2.0 μg/mL)
Study: 18838589
Drug: Ritonavir plus
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir plus raltegravir (400 mg raltegravir; 100 mg ritonavir every 12 h for 16 days with 400 mg raltegravir on day 14)
Study: 18838589
Drug: Efavirenz plus
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz plus raltegravir (400 mg raltegravir; 600 mg efavirenz once daily for 14 days with 400 mg raltegravir on day 12)
Study: 6213380
Drug: Topical benzoyl
Normalized name: benzoyl peroxide Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzoyl peroxide 5 percent
Study: 6213380
Drug: Topical benzoyl
Normalized name: benzoyl peroxide Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzoyl peroxide 5 percent in 8 percent urea
Study: 27795558
Drug: 6 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/m2 Gemtuzumab ozogamicin (GO)
Study: 25792557
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (UC) with no exercise directives, monitored by monthly telephone contact.
Study: 24461523
Drug: P. niruri
Approvals — FDA: no, EMA: no, PMDA: no
Description: P. niruri infusion (5 g/750 mL)
Study: 17824581
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with clindamycin 1%-BPO 5% topical gel plus tretinoin microsphere gel 0.04%
Study: 17824581
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with clindamycin 1%-BPO 5% topical gel plus tretinoin microsphere gel 0.1%
Study: 17824581
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with clindamycin 1%-BPO 5% topical gel plus adapalene gel 0.1%
Study: 9780616
Drug: Lacidipine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (4 mg/die)
Study: 9780616
Drug: Idroclorotiazide +
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idroclorotiazide + amiloride (50 mg every other day)
Study: 3283632
Drug: nonselective beta‐blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: nonselective beta‐blocker (timolol maleate 0.5%)
Study: 3283632
Drug: cardioselective beta‐1‐blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: cardioselective beta‐1‐blocking agent (betaxolol‐HCl 0.5%)
Study: 31112706
Drug: Aloe polysaccharide
Normalized name: Aloe Polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe polysaccharide (APS) 600 mg/day
Study: 31112706
Drug: Propolis 600
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis 600 mg/day
Study: 31112706
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of APS (420 mg/day) and propolis (180 mg/day)
Study: 23656645
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (1 g daily)
Study: 21245085
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (21-mg nicotine transdermal patch)
Study: 21245085
Drug: Placebo (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo patch)
Study: 8760987
Drug: Full angioscopic
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full angioscopic (ANG) vein preparation
Study: 1314065
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) CY 216, 48 mg subcutaneous injection and two placebo injections per day.
Study: 1314065
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UH), 5000 IU t.i.d.
Study: 3882058
Drug: Bezafibrate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (10 to 20 mg/kg/day, twice daily)
Study: 22512843
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg per day orally)
Study: 18635285
Drug: gemcitabine/oxaliplatin/vinorelbine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine/oxaliplatin/vinorelbine combination
Study: 14522634
Drug: Tacrolimus 0.1%
Normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus 0.1% and 0.03% ointment
Study: 1564133
Drug: Medication vial
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication vial with a digital timepiece cap (Phase I)
Study: 1564133
Drug: Standard medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication vial (Phase I control)
Study: 3907314
Drug: Moricizine (ethmozine)
Normalized name: moricizine hydrochloride Oral Tablet [Ethmozine]
DrugBank: Moricizine (DB00680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moricizine (ethmozine) 10 to 12 mg/kg/day, administered every 12 hours
Study: 3907314
Drug: Moricizine (ethmozine)
Normalized name: moricizine hydrochloride Oral Tablet [Ethmozine]
DrugBank: Moricizine (DB00680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moricizine (ethmozine) 10 to 12 mg/kg/day, administered every 8 hours
Study: 29949175
Drug: SGLT‐2 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGLT‐2 inhibitor in addition to routine insulin therapy
Study: 29949175
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy only
Study: 24635550
Drug: Cocaine abstinence
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine abstinence during treatment (8 or 12 weeks)
Study: 19553641
Drug: Olaparib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (400 mg twice daily)
Study: 10780808
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg) + Ethanol (0.5 g/kg)
Study: 10780808
Drug: Naltrexone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (100 mg) + Ethanol (1.0 g/kg)
Study: 10780808
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg) + Pentobarbital (150 mg)
Study: 10780808
Drug: Naltrexone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (100 mg) + Pentobarbital (300 mg)
Study: 10780808
Drug: Pentobarbital (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital (0 mg)
Study: 1719716
Drug: Modified cholera
Normalized name: Modified Cholera toxin B subunit
DrugBank: Modified Cholera toxin B subunit (DB18557)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified cholera chemical vaccine (choleragen‐toxoid + O‐antigens Inaba and Ogawa)
Study: 1719716
Drug: Commercial batch
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial batch of monovalent cholera vaccine (choleragen‐toxoid + O‐antigen Inaba)
Study: 23354911
Drug: Osteopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic treatment (5 treatment sessions)
Study: 16788707
Drug: Magnesium (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (300 mg/day)
Study: 12182509
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education about the nature, causes, prevalence and treatment of depression
Study: 8542859
Drug: Saline (Control)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (Control) 3 mL
Study: 2013674
Drug: 4 mol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mol/L fraction
Study: 2013674
Drug: 1 mol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mol/L fraction
Study: 2013674
Drug: 1 mol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mol/L and H2O fractions
Study: 7032226
Drug: Single bedtime
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bedtime dose of chlorpromazine (300 mg)